Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood. High diagnostic accuracy : Quantitative values of biomarkers are measured and entered in a unique algorithm with applied AI. Convenience : No burden of inconvenience caused due to the use of a separate diagnostic device other than blood sampling Efficiency: Provides diagnosis opportunities to more people in situations where personnel and devices are limited
Exo-PASS Exosomes contain proteins, lipids, nucleic acids, and metabolites, and can be easily enriched from biofluids, providing very valuable information for early detection and monitoring of diseases. The Ministry of Food and Drug Safety requires RNA, lipid and proteomic analyses in its guidelines for the development of exosome therapeutics, and PASS provides these analyses in an all-in-one package. Exosome RNA Sequencing: PASS enables rapid and efficient isolation of RNAs and profiling of exosome nucleic acids using qRT-PCR and novel sequencing methods. Exosome Lipidomics: We perform high-reliability and high-sensitivity analysis through an ultra-high-performance tool (UPLC, Orbitrap Exploris 480 MS) and lipid analysis experts who have been producing and interpreting analysis data for many years. Exosome Proteomics: PASS offers and performs quantification analysis that meets customer needs based on the unique expertise in exosome protein extraction. We provide reliable results through deep profiling of exosome proteome and a specialized data library. Our world-class bioinformatics research team at Bertis reviews and interprets pan-omics data (RNA/Lipid) to support in-depth research.
PASS is an analysis solution optimized for academia and pharma research. The proprietary solution was derived from proven technology and innovation embedded in Mastocheck, a proteomics-based early cancer diagnostics approved by Ministry of Food and Drug Safety (MFDS). Bertis developed the PASS solution based on its pan-omics, bioinformatics, and artificial intelligence (AI) technologies. We provide a variety of analyzes for proteomic analysis, biomarker discovery and verification, new drug development, clinical process development, etc. PASS is a platform for integrative analysis of pan-omics data, based on our proven and reliable bioinformatics analysis capabilities. Our team consists of experienced scientists with an extensive track record of research achievements spanning more than a decade in mass spectrometry-based proteomics. Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis to provide customized solutions in all fields where omics data analysis is applicable. With PASS, you can leverage Bertis scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.
Proteomics-based Early diagnosis using multiple markers provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Early diagnostic solutions BERTIS has commercialized MASTOCHECK, the worlds first proteomics-based blood test solution for early diagnosis of breast cancer, and clinical trials are being conducted on biomarkers for various cancers. Ultimately, these technologies are being used to continually expand the pipeline to allow dozens of diseases to be diagnosed with a single blood test.
Biomarker Diseases Diagnosis Blood Tests Proteomics-based early diagnosis Provides a quick and accurate solution for early diagnosis of major diseases by utilizing multiple proteomic biomarker-based blood tests. Advantages of proteomics-based early diagnosis: Proteomics-based early diagnosis determines the presence of disease by identifying proteins that are specifically expressed in diseases and using these as biomarkers to measure the quantitative values of the relevant proteins in blood. Proteomics analysis has been assessed as highly likely to be used as a universal primary screening method because analysis can be performed even with trace samples, such as a few drops of blood.
PC-PASS Protein Characterization Analysis Protein Characterization (Physicochemical property of proteins) structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars. Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities. Protein identification and quantification : Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes - Full Length-Amino acids sequencing Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches) - Improved N- and C-terminal sequencing of proteins Post-translational modification (PTM) : More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently - Disulfide bond analysis ID Total possible lankage analysis - Deamidation identification and quantification - Phosphorylation identification and quantification , phospho-proteomic analysis - Other functional modifications Glycomics : Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins - Glycosylation site determination - Glycan profiling - Site-specific glycan identification and quantification - Glycomics research with glycan enrichment
AUTOMOTIVE FUEL DIESEL OIL En590 SPECIFICATION GASOIL 10 GOST � 52368-2005 (�?N 590:2004), CLASS 1, TYPE III Unit Description Value Density at 15 degr. kg/m3 max. 845 Cetane index min. 49 Kinematic viscosity at 20 Co mm2 (cSt) Min. 2.0 / Max. 4.5 Acidity, mg KOH for 100 cm2 of fuel, max. 10 Ash content, %, max. 0.01 Sulphur content, mg/kg, max. 10 Hydrogen sulphide content Absent Copper plate test Passed Water soluble acids & alkalis Passed Content of mechanical impurities Passed Water content mg/kg 200 Flash point determined in a closed cup, Cáµ? Min. 55 Solidification temperature, Cáµ?, Max. Cloud temperature, Cáµ?, Max. 16 Filterability temperature Cáµ? -27 Fat acid methyl ether content (FAME), % 5 Bacterial contamination (IP 385), CFU /litre, Max. 1,000 Quantity: 100,000 MT for Month's CIF, Singapure
Vision Group sources Diesel Fuel EN590 10 PPM from around the world, providing clients with an energy solution that aligns with international standards. Specification: Cetane Number: Minimum 51. Density: Typically ranges from 820 to 845 kg/m�³ at 15�°C. Sulfur Content: Ultra-low sulfur content, typically not exceeding 10 mg/kg (10 ppm) Polycyclic Aromatic Hydrocarbons (PAHs): Maximum limit of 8% by mass. Distillation Temperature: At least 95% of the fuel distill at 360�°C or below Flash Point: Minimum of 55�°C. Carbon Residue: Maximum limit of 0.30% by mass on the 10% distillation residue. Water Content: Maximum of 200 mg/kg. Biodiesel Content: EN 590 diesel fuel can contain up to 7% (V/V) of Fatty Acid Methyl Ester (FAME) Oxidation Stability: Minimum of 20 hours. Acid Number: Maximum of 0.50 mg KOH/g. Ash Content: Maximum of 0.01% by mass. Others, as per specifications that are part of purchase contract
4 Ply Face Mask.
Latex Gloves.
Disposable face mask.
Nitrile gloves, syringe (luer lock or leur slip),.FOB, 100% irrevocable l/c at sight, at least one year contract period
3 ply face masks.Exporting
FFP2 respirator face masks.
Ffp2 Face Mask.
Covid19 test kit, medical clothes, face shield.
3 Ply Face Masks.
Cotton Mask .
Syringe & nitrile glove.
Kf94 Boat And Fish Shape Mask.
